Sign in

CIK 0001636651 · Non-accelerated filer<br>Smaller reporting company

Ovid Therapeutics Inc.

Sign in to watch
Ticker
OVID
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
465270895
Phone
212-776-4381
Business address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10001
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2017-06-14 Duncan Barbara Gayle Director Grant or award · Stock Option (Right to Buy) +11,627 11,627
2017-05-10 Werber Yaron CBO, CFO, Sec. and Treas. Grant or award · Employee Stock Option (Right to Buy) +93,022 93,022
2017-05-10 LEVIN JEREMY M CEO Conversion +400,150 4,586,195
2017-05-10 LEVIN JEREMY M CEO Conversion +35,461 35,461
2017-05-10 LEVIN JEREMY M CEO Conversion · Series A Preferred Stock −400,150 0
2017-05-10 LEVIN JEREMY M CEO Conversion · Series B Preferred Stock −35,461 0
2017-05-10 During Matthew President and CSO Conversion +28,245 4,307,314
2017-05-10 During Matthew President and CSO Conversion · Series A Preferred Stock −28,245 0
2017-05-10 Daly Timothy VP, Finance & Corp. Controller Grant or award · Employee Stock Option (Right to Buy) +46,510 46,510

Page 10 of 10 · 189 trades